Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation

Launched by XIAOTONG HOU · Feb 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called bivalirudin to see if it works well and is safe for patients who are on a special life-support system known as extracorporeal membrane oxygenation (ECMO). ECMO is used for patients whose hearts or lungs are not working properly, and it often requires blood thinners to prevent complications. The trial aims to compare bivalirudin with a commonly used blood thinner called unfractionated heparin to find out which is better for patients receiving this type of treatment.

To participate in this study, you must be at least 18 years old and need to be on either venovenous (VV) or venoarterial (VA) ECMO, where the medical team believes that you need blood thinning treatment. You also need to be able to sign a consent form. However, if you have had an allergic reaction to heparin or bivalirudin in the past, or if you are pregnant, you won’t be eligible to join. Participants can expect to be monitored closely during the trial to ensure their safety and the effectiveness of the medication being studied. This trial is not yet recruiting participants, so keep an eye out for updates if you or someone you know might be interested in joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old
• • 2. Accept VA-ECMO or VV-ECMO
• • 3. the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s.
• • 4. sign the informed consent form
• Exclusion Criteria:
• • 1. previous history of allergy to heparin or bivalirudin
• • 2. previous diagnosis of heparin-induced thrombocytopenia.
• • 3. the pre-random ECMO assistance time is more than 48 hours.
• • 4. pregnant female
• • 5. have participated in this study before.
• • 6. the researchers believe that there are other factors that are not suitable to participate in this study.